Elizabeth de Lange is Head of the Target Site Equilibration group of the Division of Pharmacology at the LACDR. Her research is aimed to aid in the prediction of the dose-response relationship of CNS drugs in the clinical setting, on the basis of preclinical data (translational research), and involves the identification and characterization of the rate and extent of key factors in the dose-response relationship of CNS drugs in health and in CNS disorders. Dr de Lange’s current research involves the use of intracerebral microdialysis, EEG monitoring, and PET scanning. Furthermore advanced mathematical modeling is extensively used to model and predict PKPD relationships and disease progression.

Dr. de Lange is an editor of Fluids and Barriers of the Central Nervous System (FBCNS), and editorial advisory board member of the Journal of Pharmaceutical Sciences (JPS). She has been the cofounder and (co-)Chair at the 1st, 2nd and 5th of the series of International Symposia on Microdialysis in Drug Research and Development, and Chair of the 9th International Cerebrovascular Biology Conference, Leiden, The Netherlands, 2011. Furthermore, she is the current Chair of the section “Pharmacokinetics, Pharmacodynamics and Drug Metabolism” (PPDM), the 2013-Co- and 2014 Chair of the Annual Meeting Programming Committee, and member of the International Affairs Committee of the American Association of Pharmaceutical Scientists (AAPS). With her company In Focus (www.infocus-ecmdelange.nl) she provides (in-house) courses, training and advice within her area of expertise on microdialysis, PK, PKPD, BBB, and intra-brain distribution ([email protected]).